CXCL5 and lung cancer: Besides, they blocked CXCL5 expression in SC significantly decreases the phosphorylation of AKT and GSK-3β in SC-treated lung cancer cells; PI3K inhibitor LY294002 blocks the activation of AKT/GSK-3β signaling in SC-conditioned lung cancer cells.